Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca... In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved.
- Mechanism
- Curator reviewed
Ximelagatran was the first member of the drug class of direct thrombin inhibitors that can be taken orally. Its effect is solely related to the inhibition of thrombin.
- Primary indication
- For the treatment of acute deep vein thrombosis.Curator reviewed
- Formula / weight
- C24H35N5O5 · 473.5652 g/mol (avg)
- Code names
- H 376-95
Resolves to
ZXIBCJHYVWYIKI-PZJWPPBQSA-NSMILESCCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCC1=CC=C(C=C1)C(\N)=N\O)C1CCCCC1What you can answer from here — as of March 06, 2025
Which drugs share a target with Ximelagatran, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account